Corstasis Therapeutics - About the company
Corstasis Therapeutics is an acquired company based in Henderson (United States), founded in 2018 by Benjamin Esque. It operates as a Developer of therapeutics to recover from fluid volume overload. The company has 176 active competitors, including 62 funded and 41 that have exited. Its top competitors include companies like Nimbus Therapeutics, AskBio and Madrigal Pharmaceuticals.
Company Details
Developer of therapeutics to recover from fluid volume overload. It offers a pipeline which include RSQ-777 an intranasal diuretic, RSQ-786 a sub diuretic, and RSQ-789 a subQ diuretic for fluid overload associated with congestive heart failure, liver, and kidney disease.
- Website
- corstasis.com
- Email ID
- *****@corstasis.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2018
Location
Henderson, United States
Stage
Acquired
Investors
Ranked
57th among 176 active competitors
Employee Count
10 as on Jun 30, 2026
Exit Details
Acquired by Esperion Therapeutics (Mar 03, 2026)
Corstasis Therapeutics's acquisition details
Corstasis Therapeutics got acquired by Esperion Therapeutics on Mar 03, 2026 at an acquisition amount of $*****.
Click here to take a look at Corstasis Therapeutics's acquisition in detail
Sign up to download Corstasis Therapeutics' company profile
Corstasis Therapeutics's funding and investors
Corstasis Therapeutics is a funded company. Corstasis Therapeutics has 1 institutional investor.
View details of Corstasis Therapeutics's funding rounds and investors
Corstasis Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of Corstasis Therapeutics is Benjamin Esque. Benjamin Esque is the CEO of Corstasis Therapeutics.
Here are the details of Corstasis Therapeutics' key team members:
- Benjamin Esque: Founder & CEO of Corstasis Therapeutics.
View details of Corstasis Therapeutics's Founder profiles and Board Members
Corstasis Therapeutics' employee count trend
Corstasis Therapeutics has 10 employees as of Jun 26. Here is Corstasis Therapeutics's employee count trend over the years:
Uncover Corstasis Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Corstasis Therapeutics's Competitors and alternates
Top competitors of Corstasis Therapeutics include Nimbus Therapeutics, AskBio and Madrigal Pharmaceuticals. Here is the list of Top 10 competitors of Corstasis Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 68/100 | |
2nd |  AskBio 2001, Durham (United States), Acquired | Developer of AAV technologies for treating genetic and complex disorders | $235M | 68/100 | |
3rd | Madrigal Pharmaceuticals 2011, Conshohocken (United States), Acquired | Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis | $38.4M | 66/100 | |
4th |  Mammoth 2017, Brisbane (United States), Series D | Provider of molecular diagnostics platform by using CRISPR technology | $271M | 65/100 | |
5th | Mission Therapeutics 2011, Cambridge (United Kingdom), Series D | Developer of small molecule inhibitors targeting specific disease associated enzymes | $192M | 64/100 | |
6th | Developer of a novel treatment for metabolic diseases | $138M | 64/100 | ||
7th | Intercept Pharmaceuticals 2002, New York City (United States), Acquired | Developer of therapeutics to treat progressive non-viral liver diseases | $121M | 63/100 | |
8th | Developer of genetic medicines for treating rare heart muscle conditions | $80.6M | 62/100 | ||
9th |  Mirum Pharmaceuticals 2018, Menlo Park (United States), Public | Developer of small molecule based therapeutics to treat rare diseases | $120M | 61/100 | |
10th | Developer of drugs for heart failure treatment | $36.5M | 61/100 | ||
57th |  Corstasis Therapeutics 2018, Henderson (United States), Acquired | Developer of therapeutics to recover from fluid volume overload | - | 44/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Corstasis Therapeutics's competitors? Click here to see the top ones
Corstasis Therapeutics's Investments and acquisitions
Corstasis Therapeutics has made no investments or acquisitions yet.
Reports related to Corstasis Therapeutics
Here is the latest report on Corstasis Therapeutics's sector:
News related to Corstasis Therapeutics
Media has covered Corstasis Therapeutics for a total of 7 events in the last 1 year, 1 of them has been about company updates and 1 about partnerships.
•
•
•
•
•
•
Corstasis Therapeutics Appoints Sanjeev Narula to Strategic Advisory BoardBusiness Wire•Jul 23, 2025•Corstasis Therapeutics
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Corstasis Therapeutics
Explore our recently published companies
- WL Excavation - Winchester based, Unfunded company
- Strategic Branding Matters - Manhattan Beach based, 2022 founded, Unfunded company
- Shy Luxury Hair - Unfunded company
- Rockwell and Page - Unfunded company
- BatugaTech - Princeton based, Unfunded company
- Queue Receipts - United Kingdom based, Unfunded company
